ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,431.60
-0.04%
US Tech 100
19,168.00
0.52%
다우존스 지수
38,589.16
-0.15%
Bitcoin
66,158.70
0.23%
Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Agios Pharmaceuticals Inc (AGIO)

  7. Agios Pharmaceuticals Inc (AGIO) 뉴스

AGIO

Agios Pharmaceuticals (AGIO)

Agios Pharmaceuticals Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:AGIO
일자시간출처헤드라인심볼기업
2024/06/1521:45GlobeNewswire Inc.Agios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid CongressNASDAQ:AGIOAgios Pharmaceuticals Inc
2024/06/0805:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGIOAgios Pharmaceuticals Inc
2024/06/0622:00GlobeNewswire Inc.Updated Time: Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 at 8:40 am ETNASDAQ:AGIOAgios Pharmaceuticals Inc
2024/06/0608:50Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AGIOAgios Pharmaceuticals Inc
2024/06/0605:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGIOAgios Pharmaceuticals Inc
2024/06/0319:30GlobeNewswire Inc.Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-ThalassemiaNASDAQ:AGIOAgios Pharmaceuticals Inc
2024/05/3105:05GlobeNewswire Inc.Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024NASDAQ:AGIOAgios Pharmaceuticals Inc
2024/05/2820:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGIOAgios Pharmaceuticals Inc
2024/05/2820:00GlobeNewswire Inc.Agios Announces $905 Million Purchase Agreement for Vorasidenib RoyaltyNASDAQ:AGIOAgios Pharmaceuticals Inc
2024/05/1423:00GlobeNewswire Inc.Agios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid CongressNASDAQ:AGIOAgios Pharmaceuticals Inc
2024/05/0620:00GlobeNewswire Inc.Agios to Present at the BofA Securities 2024 Health Care Conference on May 16, 2024NASDAQ:AGIOAgios Pharmaceuticals Inc
2024/05/0320:00GlobeNewswire Inc.Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024NASDAQ:AGIOAgios Pharmaceuticals Inc
2024/05/0220:00GlobeNewswire Inc.Agios Reports Business Highlights and First Quarter 2024 Financial ResultsNASDAQ:AGIOAgios Pharmaceuticals Inc
2024/04/1820:00GlobeNewswire Inc.Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024NASDAQ:AGIOAgios Pharmaceuticals Inc
2024/04/0920:00GlobeNewswire Inc.Agios Publishes 2024 Environmental, Social and Governance (ESG) ReportNASDAQ:AGIOAgios Pharmaceuticals Inc
2024/03/0808:47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGIOAgios Pharmaceuticals Inc
2024/03/0606:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGIOAgios Pharmaceuticals Inc
2024/03/0606:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGIOAgios Pharmaceuticals Inc
2024/03/0606:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGIOAgios Pharmaceuticals Inc
2024/03/0606:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGIOAgios Pharmaceuticals Inc
2024/03/0606:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGIOAgios Pharmaceuticals Inc
2024/03/0521:00GlobeNewswire Inc.Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024NASDAQ:AGIOAgios Pharmaceuticals Inc
2024/03/0206:27Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AGIOAgios Pharmaceuticals Inc
2024/03/0206:26Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AGIOAgios Pharmaceuticals Inc
2024/03/0206:25Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AGIOAgios Pharmaceuticals Inc
2024/03/0206:22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AGIOAgios Pharmaceuticals Inc
2024/03/0106:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGIOAgios Pharmaceuticals Inc
2024/02/2806:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGIOAgios Pharmaceuticals Inc
2024/02/2711:21Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AGIOAgios Pharmaceuticals Inc
2024/02/2307:43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGIOAgios Pharmaceuticals Inc
 검색 관련기사 보기:NASDAQ:AGIO

최근 히스토리

USOTC
YRZUF
Yorozu (PK)
BOV
R1OK34
Rockwell Automation
TG
BDAC
ABN AMRO Bank
LSE
EROS
Eros
BIT
P1YFK9
NLBNPIT1YFK9 20351221 0....
USOTC
MTLHY
Mitsubishi Chemical (PK)
NASDAQ
ADSEW
ADD TEC Energy
BIT
P1QZW8
BNP Paribas Issuance
FTSE
3XEC
FTSE E300 ex Euro Blanc
BIT
IEG
Italian Exhibition
BIT
P1CP84
BNP Paribas Issuance
AQEU
HBMD
Hornbach Baumarkt
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유